HEAD & NECK CANCERS

The phase 2/3 AHEAD-MERIT trial will continue to evaluate patients with HPV-positive head and neck squamous cell carcinoma for its second primary end point of overall survival.

A cisplatin patch achieves 95.5% complete responses in early oral lesions, helping patients avoid surgery with durable control and minimal systemic toxicity.

INBRX-106 plus pembrolizumab boosts response rates in first-line PD-L1–positive head and neck cancer, with striking benefits in HPV-positive patients and manageable side effects.

FDA grants breakthrough status to JBS-003 F-MISO PET imaging, aiming to personalize radiation in HPV-positive throat cancer by safely reducing dose for nonhypoxic tumors.

This analysis builds on results from the phase 3 KEYNOTE-689 trial of perioperative pembrolizumab in head and neck squamous cell carcinoma.

Neoadjuvant leukocyte interleukin injection demonstrated efficacy in a biomarker-selected population, supporting a planned phase 3 trial in the locally advanced resectable oral cancer setting.

The sBLA for subcutaneous amivantamab is supported by results from the phase 1b/2 OrigAMI-4 study.

The 100% response rate for the combination was achieved in older patients with locally advanced or metastatic head and neck squamous cell carcinoma.

An ongoing dose expansion phase of the trial is evaluating CRB-701 plus pembrolizumab for first-line OPSCC.

The patients with HNSCC had already been treated with immune checkpoint inhibitors and platinum-based chemotherapy.

"These findings support carboplatin-based IC-CCRT as a promising alternative treatment option for LA-NPC," Jian Guan, MD.

The AKT inhibitor ipatasertib resulted in 41% overall response rate when combined with pembrolizumab in head and neck squamous cell carcinoma.

Emiltatug ledadotin is a B7-H4–directed antibody-drug conjugate that has shown antitumor activity in adenoid cystic carcinoma and other solid tumors.

INBRX-106 may act as a costimulatory agent and enhance pembrolizumab outcomes in head and neck squamous cell carcinoma.

The FDA has agreed on the design of two phase 3 trials of the antibody-drug conjugate CRB-701 in HNSCC and cervical cancer.

Dr Mehra discussed HPV-positive oropharyngeal cancer, focusing on balancing high cure rates while minimizing toxicity through careful patient selection.

Proton therapy showed an advantage in early toxicity mitigation vs radiotherapy in patients with oropharyngeal squamous cell carcinoma.

Positive efficacy signals in progression-free survival (PFS) and objective response rate (ORR) did not translate into an overall survival (OS) benefit for first-line lenvatinib (Lenvima) plus pembrolizumab (Keytruda) in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Three-year follow-up data from the phase 3 RATIONALE-309 trial show that tislelizumab plus chemotherapy provides durable progression-free survival and a clinically meaningful overall survival advantage over placebo in recurrent or metastatic nasopharyngeal carcinoma.

Clinical validation results show changes in methylated circulating tumor DNA (ctDNA) measured prior to treatment initiation and before cycle 3 of therapy were strongly associated with objective response and clinical benefit.

The FDA granted breakthrough therapy designation to Rybrevant Faspro based on data from the phase 1b/2 OrigAMI-4 study (NCT06385080).

The IMMUNEBOOST-HPV trial investigated whether adding nivolumab (Opdivo) immunotherapy before standard chemoradiation could improve outcomes for patients with high-risk oropharyngeal cancer.

New research uncovers how genetic ancestry influences head and neck cancer biology, paving the way for personalized treatment strategies and improved patient outcomes.